We are pleased to announce the new dates and location for the Trans-Pacific Health Sciences Dialogue 2015:
October 14-15, 2015

The Joseph B. Martin Conference Center at Harvard Medical School, Boston, MA

More information coming soon.

Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!

Day 1 PhotosDay 2 Photos

About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.

Sponsors

Sponsors_200px

Supporters

Supporters_200px

Who Should Attend

WhoShouldAttend

The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • NICE backs Harvoni for some HCV patientsThe U.K.'s NICE published draft guidance recommending Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) as a cost-effective treatment for certain subpopulations of patients with HCV genotypes 1 and 4 at a list price of L38,980 ($60,017) for a 12-week course. Comments are due March 23.

    NICE recommended an 8-week course of Harvoni for treatment-naive, non-cirrhotic patients with HCV genotype 1. The committee recommended a 12-week course for treatment-naive genotype 1 and 4 patients with cirrhosis and for previously-treated, non-cirrhotic patients with genotypes 1 or 4. The draft guidance did not recommend Harvoni for previously-treated patients with cirrhosis, nor to treat genotype 3.

    The European Commission approved Harvoni last November to treat chronic HCV genotype 1, 3 and 4 infection (see BioCentury Extra, Nov. 18, 2014).

    Harvoni's U.K. list price is 36% lower than its $94,500 WAC in the U.S. FDA approved the drug in October (see BioCentury Extra, Oct. 10, 2014).

    Harvoni is a once-daily fixed-dose combination of 90 mg of the HCV NS5A protein inhibitor ledipasvir plus 400 mg of Gilead's nucleotide analog HCV NS5B polymerase inhibitor Sovaldi sofosbuvir.
Read more

Industry News from PharmAsia

  • Daewoong Inks Autotelic Deal To Help International ExpansionAfter a fairly smooth launch for its combination drug Olostar in South Korea last year, Daewoong is now taking the product into global markets as part of its international expansion strategy.<img src="//feeds.feedburner.com/~r/_PharmAsiaNews/~4/L51Y1uDV13g" height="1" width="1" alt="" />
Read more